Comparative effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor antagonism on plasma fibrinolytic balance in humans

Hypertension

Volumn 34, Issue 2, 1999, Pages 285-290

  Brown, Nancy J ^a,c   Agirbasli, Mehmet ^a   Vaughan, Douglas E ^a,b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Angiotensin II; Plasminogen activators; Renin

Indexed keywords

ALDOSTERONE; ANGIOTENSIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOSARTAN; QUINAPRIL; RENIN;

ADULT; ANTIGEN BINDING; ARTICLE; BODY MASS; CLINICAL ARTICLE; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG RECEPTOR BINDING; ENZYME INHIBITION; FEMALE; FIBRINOLYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SALT INTAKE;

EID: 0032868908     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.34.2.285     Document Type: Article

References (53)

1. Alderman MH, Madhavan S, Ooi WL, Cohen H, Sealey JE, Laragh JH. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med. 1991;324: 1098-1104.
2. Brunner HR, Laragh JH, Baer L, Newton MA, Goodwin FT, Krakoff LR, Bard RH, Buhler FR. Essential hypertension: renin and aldosterone, heart attack and stroke. N Engl J Med. 1972;286:441-449.
3. Chobanian AV, Haudenschild CC, Nickerson C, Drago R. Anti-atherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit. Hypertension. 1990;15:327-331.
4. Fennessy PA, Campbell JH, Campbell GR. Perindopril inhibits both the development of atherosclerosis in the cholesterol-fed rabbit and lipoprotein binding to smooth muscle cells in culture. Atherosclerosis. 1994;106:29-41.
5. Pfeffer MA, Braunwald EA, Moye LA, Basta L, Brown EJ Jr, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, Klein M, Lamas GA, Packer M, Rouleau J, Rouleau JL, Rutherford J, Wertheimer JH, Hawkins CM. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 1992; 327:669-677.
6. Yusuf S, Pepine CJ, Garces C, Pouleur H, Salem D, Kostis J, Benedict C, Rousseau M, Bourassa M, Pitt B. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet. 1992;340:1173-1178.
7. Vaughan DE, Lazos SA, Tong K. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. J Clin Invest. 1995;95:995-1001.
8. Kerins DM, Hao Q, Vaughan DE. Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV. J Clin Invest. 1995;96:2515-2520.
9. Saksela O, Rifkin DB. Cell-associated plasminogen activation: regulation and physiologic functions. Anna Rev Cell Biol. 1988;4:93-126.
10. Chomiki N, Henry M, Alessi MC, Anfosso F, Juhan-Vague I. Plasminogen activator inhibitor-1 expression in human liver and healthy or atherosclerotic vessel walls. Thromb Haemost. 1994;72:44-53.
11. Schneiderman J, Sawdey MS, Keeton MR, Bordin GM, Bernstein EF, Dilley RB, Loskutoff DJ. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci U S A. 1992;89:6998-7002.
12. Hamsten A, Wiman B, deFaire U, Blomback M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med. 1985;313:1557-1563.
13. Hamsten A, de Fairde U, Walldius G, Dahlen G, Szamosi A, Landou C, Blomback M, Wiman B. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet. 1987;2:3-9.
14. van Leeuwen RT, Kol A, Andreotti F, Kluft C, Maseri A, Sperti G. Angiotensin II increases plasminogen activator inhibitor type 1 and tissue-type plasminogen activator messenger RNA in cultured rat aortic smooth muscle cells. Circulation. 1994;90:362-368.
15. Vaughan DE, Rouleau J-L, Ridker PM, Arnold JMO, Menapace FJ, Pfeffer MA, on behalf of the HEART Study Investigators. Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction. Circulation. 1997;96:442-447.
16. Brown NJ, Vaughan DE. Effect of activation and inhibition of the renin angiotensin system on plasma PAI-1 in humans. Hypertension. 1998;32: 965-971.
17. Moriyama Y, Ogawa H, Oshima S, Takazoe K, Honda Y, Hirashima O, Arai H, Sakamoto T, Sumida H, Suefuji H, Kaikita K, Yasue H. Captopril reduced plasminogen activator inhibitor activity in patients with acute myocardial infarction. Jpn Circ J. 1997;61:308-314.
18. Mugellini A, Zoppi A, Corradi L, Lusardi P, Preti P, Marasi G, Fogari R. Effect of trandolapril and losartan on plasma PAI-1 and fibrinogen in hypertensive post-menopausal women. Am J Hypertens. 1998;11:112A. Abstract.
19. Litchfield WR, Vaughan DE, Brown NJ, Wyckoff JA, Weiss RJ, Williams GH. Activation of the renin-angiotensin system through dietary sodium restriction increases plasminogen activator inhibitor type 1 levels in essential hypertension. Hypertension. 1997;30:481. Abstract.
20. Oshima S, Ogawa H, Mizuno Y, Yamashita S, Noda K, Saito T, Sumida H. Suefuji H, Kaikita K, Soejima H, Yasue H. The effects of the angiotensin-converting enzyme inhibitor imidapril on plasma plasminogen activator inhibitor activity in patients with acute myocardial infarction. Am Heart J. 1997;134:961-966.
21. Seljeflot I, Moan A, Kjeldsen S, Sandvik E, Arnesen H. Effect of angio-tensin II receptor blockade on fibrinolysis during acute hyperinsulinemia in patients with essential hypertension. Hypertension. 1996;27: 1299-1304.
22. Goldberg M, Bradstreet T, McWilliams E, Tanaka W, Lipert S, Bjornsson T, Waldman S, Osborne B, Pivadori L, Lewis G. Biochemical effects of losartan, a nonpeptide angiotensin II receptor antagonist, on the renin-angiotensin-aldosterone system in hypertensive patients. Hypertension. 1995;25:37-46.
23. Gainer JV, Morrow JD, King DJ, Brown NJ. Effect of bradykinin receptor blockade on the response to angiotensin-converting enzyme inhibitor in normotensive and hypertensive subjects. N Engl J Med. 1998;339:1285-1292.
24. Cockcroft JR, Sciberras DG, Goldberg MR, Ritter JM. Comparison of angiotensin-converting enzyme inhibition with angiotensin II receptor antagonism in the human forearm. J Cardiovasc Pharmacol. 1993;22: 579-784.
25. Brown NJ, Gainer JV, Stein CM, Vaughan DE. Bradykinin stimulates tissue plasminogen activator release in human vasculature. Hypertension. 1999;33:1431-1435.
26. Grimaudo V, Hauert J, Backmann F, Kruithof EKO. Diurnal variation of the fibrinolytic system. Thromb Haemost. 1988;59:495-499.
27. Verheijen JH, Chang GTG, Kluft C. Evidence for the occurrence of a fast acting inhibitor of tissue-type plasminogen activator in plasma. Thromb Haemost. 1984;51:392-395.
28. Ridker PM, Gaboury CL, Conlin PR, Seely EW, Williams GH, Vaughan DE. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II. Circulation. 1993;87:1969-1973.
29. Workman RJ, Sussman CR, Burkitt DW, Liddle GW. Circulating levels of angiotensin I measured by radioimmunoassay in hypertensive subjects. J Lab Clin Med. 1979;93:847-856.
30. Legro RS, Finegood D, Dunaif A. A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1998;83:2694-2698.
31. Wright RA, Flapan AD, Alberti KG, Ludlam CA, Fox KAA. Effects of captopril therapy on endogenous fibrinolysis in men with recent uncomplicated myocardial infarction. J Am Coll Cardiol. 1994;24:67-73.
32. Lottermoser K, Wostmann B, Weisser B, Hertfelder HJ, Vetter H, Dusing R. Effects of captopril on fibrinolytic function in healthy humans. Am J Hypertens. 1997;10:129A. Abstract.
33. Trifiletti A, Barbera N, Scamardi R, Bagnato L, Pizzoleo MA, Nevoso A, Lasco A, Pedulla M, Frisina N. Effects of medium-term antihypertensive therapy on haemostatic parameters in patients with essential hypertension. Haemostasis. 1997;27:35-38.
34. Jansson JH, Boman K, Nilsson TK. Enalapril related changes in the fibrinolytic system in survivors of myocardial infarction. Eur J Clin Pharmacol. 1993;44:485-488.
35. Bridges AB, McLaren M, Belch JJ. A comparative study of captopril and enalapril on endothelial cell function in congestive heart failure patients. Analogy. 1995;46:811-817.
36. Sayer JW, Gutteridge C, Syndercombe-Court D, Wilkinson P, Timmis AD. Circadian activity of the endogenous fibrinolytic system in stable coronary artery disease: effects of beta-adrenoreceptor blockers and angiotensin-converting enzyme inhibitors. J Am Coll Cardiol. 1998;32: 1962-1968.
37. Lottermoser K, Weisser B, Hertfelder HJ, Wostmann B, Vetter H, Dusing R. Antihypertensive drug treatment and fibrinolytic function. Am J Hypertens. 1998;11:378-384.
38. Juhan-Vague I, Alessi MC. PAI-1, obesity, insulin resistance and risk of cardiovascular events. Thromb Haemost. 1997;78:656-660.
39. Carvalho CR, Thirone AC, Gontijo JA, Velloso LA, Saad MJ. Effect of captopril, losartan, and bradykinin on early steps of insulin action. Diabetes. 1997;46:1950-1957.
40. Laakso M, Karjalainen L, Lempiainen-Kuosa P. Effects of losartan on insulin sensitivity in hypertensive subjects. Hypertension. 1996;28: 392-396.
41. Nordt TK, Sawa H, Fujii S, Bode C, Sobel BE. Augmentation of arterial endothelial cell expression of the plasminogen activator inhibitor type-1 (PAI-1) gene by proinsulin and insulin in vivo. J Mol Cell Cardiol. 1998;30:1535-1543.
42. Brown NJ, Chen Y-Q, Vaughan DE. Synergistic effects of aldo and Ang II on PAI-1 expression. Circulation. 1998;98:1519. Abstract.
43. Burnier M, Rutschmann B, Nussberger J, Versaggi J, Shahinfar S, Waeber B, Brunner H. Salt-dependent renal effects of an angiotensin II antagonist in healthy subjects. Hypertension. 1993;22:339-347.
44. Ohtawa M, Takayama F, Saitoh K, Yoshinaga T, Nakashima M. Pharmacokinetics and biochemical efficacy after single and multiple oral administration of losartan, an orally active nonpeptide angiotensin II receptor antagonist, in humans. Br J Clin Pharmacol. 1993;35:290-297.
45. Goldberg MR, Tanaka W, Barchowsky A, Bradstreet TE, McCrea J, Lo MW, McWilliams EJ Jr, Bjornsson TD. Effects of losartan on blood pressure, plasma renin activity, and angiotensin II in volunteers. Hypertension. 1993;21:704-713.
46. Gandhi SK, Ryder DH, Brown NJ. Losartan blocks aldosterone and renal vascular responses to angiotensin II in humans. Hypertension. 1996;28: 961-966.
47. Vaughan DE, Rouleau J-L, Pfeffer MA. Role of the fibrinolytic system in preventing myocardial infarction. Eur Heart J. 1995;16:31-36.
48. Alessi MC, Juhan-Vague I, Declerck PJ, Collen D. Molecular forms of plasminogen activator inhibitor-1 (PAI-1) and tissue-type plasminogen activator (tPA) in human plasma. Thromb Res. 1991;62:275-285.
49. Lucore CL, Sobel BE. Interactions of tissue-type plasminogen activator with plasma inhibitors and their pharmacologic implications. Circulation. 1988;77:660-669.
50. Chandler WL, Alessi MC, Aillaud MF, Henderson P, Vague P, Juhan-Vague I. Clearance of tissue plasminogen activator (tPA) and tPA/plasminogen activator Inhibitor type 1 (PAI-1) complex relationship to elevated tPA antigen in patients with high PAI-1 activity levels. Circulation. 1997;96:761-768.
51. Hornig B, Arakawa N, Smolarski R, Schieffer B, Drexler H. Concomitant enhancement of NO-mediated vasodilation and pro-fibrinolytic activity by ACE inhibition in patients with coronary artery disease. Circulation. 1997;96. Abstract.
52. Smith D, Gilbert M, Owen WG. Tissue plasminogen activator release in vivo in response to vasoactive agents. Blood. 1985;66:835-839.
53. Chandler WL, Veith RC, Fellingham GW, Levy WC, Schwartz RS, Cerqueira MD, Kahn SE, Larson VG, Cain KC, Beard JC. Fibrinolytic response during exercise and epinephrine infusion in the same subjects. J Am Coll Cardiol. 1992;19:1412-1420